Search

Roche Holding AG

Open

BrancheGesundheitswesen

355.2 1.14

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

342.2

Max

356

Schlüsselkennzahlen

By Trading Economics

Einkommen

3.7B

Verkäufe

16B

KGV

Branchendurchschnitt

29.736

89.037

Dividendenrendite

2.74

Gewinnspanne

23.266

Angestellte

103,249

EBITDA

6.5B

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

2.74%

2.18%

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

278B

Vorheriger Eröffnungskurs

354.06

Vorheriger Schlusskurs

355.2

Nachrichtenstimmung

By Acuity

13%

87%

19 / 360 Ranking in Healthcare

Roche Holding AG Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

18. Nov. 2025, 11:04 UTC

Wichtige Markttreiber

Roche Shares Rise After Breast-Cancer Pill Shows Positive Results in Trial

23. Okt. 2025, 09:32 UTC

Ergebnisse

Roche Raises Full-Year Earnings Outlook as U.S. Drug-Pricing Talks Continue -- Update

23. Okt. 2025, 05:54 UTC

Ergebnisse

Roche Raises Full-Year Earnings Outlook

1. Okt. 2025, 08:54 UTC

Wichtige Markttreiber

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

18. Sept. 2025, 14:01 UTC

Akquisitionen, Fusionen, Übernahmen

Roche to Buy Maker of Fatty Liver Treatment 89bio for Up to $3.5 Billion -- 2nd Update

18. Sept. 2025, 10:05 UTC

Wichtige Markttreiber
Akquisitionen, Fusionen, Übernahmen

89bio Shares Soar Premarket on Takeover by Roche

18. Sept. 2025, 10:04 UTC

Akquisitionen, Fusionen, Übernahmen

Roche to Buy Maker of Fatty Liver Treatment 89bio for Up to $3.5 Billion -- Update

18. Sept. 2025, 05:37 UTC

Akquisitionen, Fusionen, Übernahmen

Roche to Buy 89bio for Up to $3.5 Billion

16. Jan. 2026, 17:03 UTC

Market Talk

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

12. Jan. 2026, 14:50 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Pharma Sector Can Spend Big on M&A -- Market Talk

22. Dez. 2025, 08:48 UTC

Market Talk

U.S. Administration's Deals With Big Pharma Unveil Pricing Uncertainty -- Market Talk

19. Nov. 2025, 12:47 UTC

Market Talk

Roche's Breast Cancer Drug Trial Results Surprise Positively -- Market Talk

10. Nov. 2025, 12:16 UTC

Market Talk
Ergebnisse

Roche Results for MS-Treatment Candidate Look Encouraging -- Market Talk

23. Okt. 2025, 09:19 UTC

Market Talk
Ergebnisse

Roche's Sales Slow, But Drug Pipeline Could Support Long-Term Growth -- Market Talk

23. Okt. 2025, 09:11 UTC

Market Talk
Ergebnisse

Roche Sales Miss Driven by Underperformance of Key Drugs -- Market Talk

23. Okt. 2025, 05:09 UTC

Ergebnisse

Roche 3Q Sales Up 6% At CER

23. Okt. 2025, 05:07 UTC

Ergebnisse

Roche 3Q Sales CHF14.92B

23. Okt. 2025, 05:07 UTC

Ergebnisse

Analysts Had Seen 3Q Sales At CHF15.17B

23. Okt. 2025, 05:07 UTC

Ergebnisse

Roche See Core Earnings Per Share Growth In High-Single to Low-Double-Digit Range At CER

23. Okt. 2025, 05:05 UTC

Ergebnisse

Roche Expects An Increase In Group Sales In Mid-Single-Digit Range At CER

23. Okt. 2025, 05:04 UTC

Ergebnisse

Roche: Group Sales Up 7% At Constant Exchange Rates In First Nine Months

23. Okt. 2025, 05:02 UTC

Ergebnisse

Roche Had Seen High-Single-Digit 2025 Core Earnings Per Share Growth at CER

23. Okt. 2025, 05:02 UTC

Ergebnisse

Roche Had Seen Mid-Single-Digit 2025 Sales Growth At Constant Exchange Rates

23. Okt. 2025, 05:02 UTC

Ergebnisse

Roche 9-Mos CH45.9B

23. Okt. 2025, 05:01 UTC

Ergebnisse

Roche Raises 2025 View

1. Okt. 2025, 20:33 UTC

Akquisitionen, Fusionen, Übernahmen

Roche Begins Tender Offer for 89bio Pursuant to Previously Announced Merger Agreement

1. Okt. 2025, 09:05 UTC

Heiße Aktien

Stocks to Watch Wednesday: Nike, Lithium Americas, Arm, Occidental -- WSJ

18. Sept. 2025, 14:12 UTC

Akquisitionen, Fusionen, Übernahmen

89bio Stock Soars 86%. Why Roche Is Buying the Biopharma Company for $3.5 Billion. -- Barrons.com

18. Sept. 2025, 07:37 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Roche's 89bio Acquisition Gives Its Drug Pipeline Potential Blockbuster -- Market Talk

18. Sept. 2025, 05:09 UTC

Akquisitionen, Fusionen, Übernahmen

89bio Says Deal Reflects Potential of Pegozafermin Drug Candidate

Roche Holding AG Prognose

Rating-Konsens

By TipRanks

0 ratings

0

Buy

0

Halten

0

Sell

Stimmung

By Acuity

19 / 360 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.
help-icon Live chat